Telomir Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
TELO$0.69-2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations (unaudited)
CONDENSED STATEMENTS OF OPERATIONS
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenues | $— | $— |
| Operating costs: | ||
| General and administrative expenses | 573,539 | 1,850,786 |
| Research and development expenses | 467,797 | 336,996 |
| Total operating costs | 1,041,336 | 2,187,782 |
| Interest income | 51,644 | 8,000 |
| Interest expense | (1,255) | (46) |
| Total other income, net | 50,389 | 7,954 |
| Net loss | $(990,947) | $(2,179,828) |
| Basic and diluted net loss per share | $(0.03) | $(0.07) |
| Basic and diluted weighted average common stock shares outstanding | 34,380,971 | 29,762,671 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.